亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Combination of TREC Measurement and Next-Generation Sequencing in Newborn Screening for Severe Combined Immunodeficiency: A Pilot Program in Japan

新生儿筛查 严重联合免疫缺陷 人口 生物 无症状的 移植 免疫缺陷 原发性免疫缺陷 医学 基因 免疫学 遗传学 内科学 免疫系统 环境卫生
作者
Hideki Muramatsu,Daiei Kojima,Yusuke Okuno,Shinsuke Kataoka,Yoko Nakajima,Tetsuya Ito,Ikuya Tsuge,Sakai Yoshimi,Tomoaki Kato,Seiji Kojima,Yoshiyuki Takahashi
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 3717-3717 被引量:6
标识
DOI:10.1182/blood-2018-99-118261
摘要

Abstract INTRODUCTION Severe combined immunodeficiency disease (SCID) is the most severe form of primary immunodeficiency disorders (PIDs). Impaired cellular and humoral immunity renders the affected infants susceptible to various infections and results in death within the first 2 years of life. Affected infants are asymptomatic at birth, untreated disease leads to death, and prompt treatment (i.e., hematopoietic stem cell transplantation, gene therapy, or enzyme replacement therapy) is linked to significant improvement in outcome. Thus, SCID meets the disease criteria for newborn screening (NBS). The T-cell receptor excision circle (TREC) is an excellent marker of recently formed T cells, and quantitative PCR-based measurement of TREC is an excellent tool in population-based NBS for SCID. Recent progress in next-generation sequencing (NGS) has enabled the simultaneous sequencing of numerous nucleic acids, detecting single nucleotide changes as well as copy number variants. We launched a pilot newborn optional screening program for SCID, combining the measurement of TREC and NGS in Japan. PATIENTS AND METHODS We measured TREC copy number using the Enlite™ Neonatal TREC assay (Perkin Elmer, Turku, Finland), which utilizes the duplex amplification of TREC and beta-actin in the same reaction for each specimen. We used TREC negative cutoffs as follows: TREC copy number of <30 copies/μL and beta-actin copy number of ≥50 copies/μL. In patients with TREC negative results, genomic DNA was subjected to DNA capture designed using SureDesign (Agilent, Santa Clara, USA), covering a total of 349 genes associated with PIDs, inherited bone marrow failure syndromes, and the 22q11.2 region. Target capture, enrichment, and indexing were performed according to the manufacturer's instructions. Generated libraries were sequenced using a HiSeq 2500 platform (Illumina, San Diego, USA). This study was approved by the ethical committees of the Nagoya University Graduate School of Medicine and Fujita Health University. RESULTS From April 2017 to March 2018, we screened a total of 22,865 newborns, covering 57% of the total number of births in the Aichi prefecture, Japan. We identified 48 (0.21%) newborns with TREC negative results. These newborns were referred to the Nagoya University Hospital or Fujita Health University Hospital and received thorough immunological examination, including target capture sequencing. Among them, 12 (25%) newborns had background diseases, including Down syndrome (n = 4), gastrointestinal defects (n = 3), congenital diaphragmatic hernia (n = 2), congenital chylothorax (n = 2), and severe congenital heart anomaly (n = 1). Immunological assessment identified 11 (23%) infants with lymphocytopenia (<1500 /μL). These infants avoided live vaccines and received appropriate interventions to prevent infection. Using target sequencing analyses, we identified four patients with PIDs, including 22q11.2 deletion syndrome (n = 2), Wiskott‒Aldrich syndrome (n = 1), and combined immunodeficiency with an unknown causative gene (n = 1). CONCLUSION We successfully launched a pilot newborn optional screening program for SCID, combining the measurement of TREC and NGS in Japan. We did not identify typical SCID patients probably because of the relatively small sample size. However, this newborn screening program, incorporating an NGS assay as a second test, achieved early accurate diagnoses of patients with other PIDs with TREC negative results. Consequently, this program may facilitate patient management and optimize treatment outcomes. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lzk完成签到,获得积分10
7秒前
zzmine完成签到 ,获得积分10
12秒前
00hello00发布了新的文献求助10
18秒前
懵懂的小之完成签到,获得积分10
19秒前
田様的应助被浮云采纳,获得10
24秒前
酷波er的应助被00hello00采纳,获得10
26秒前
27秒前
32秒前
34秒前
浮云发布了新的文献求助10
37秒前
芒果完成签到,获得积分20
38秒前
46秒前
50秒前
浮云发布了新的文献求助10
54秒前
54秒前
1分钟前
1分钟前
复杂曼荷完成签到,获得积分10
1分钟前
may完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
英俊的铭的应助被邓倩采纳,获得10
1分钟前
Maestro_S的应助被呵呵采纳,获得10
1分钟前
00hello00发布了新的文献求助10
1分钟前
1分钟前
1分钟前
仁爱的鞋子完成签到,获得积分10
1分钟前
安详老鼠完成签到,获得积分10
1分钟前
2分钟前
2分钟前
Shu完成签到,获得积分10
2分钟前
刻苦的煎蛋完成签到,获得积分10
2分钟前
庾傀斗发布了新的文献求助10
2分钟前
ssgg完成签到,获得积分10
2分钟前
辛勤诗兰完成签到,获得积分10
2分钟前
2分钟前
不爱写论文完成签到,获得积分10
2分钟前
HaoZhang发布了新的文献求助10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195111
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872823
捐赠科研通 7794997
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609